Please login to the form below

Not currently logged in
Email:
Password:

aducanumab

This page shows the latest aducanumab news and features for those working in and with pharma, biotech and healthcare.

Tecfidera successor’s side-effect profile boosts Biogen

Tecfidera successor’s side-effect profile boosts Biogen

Biogen had been hoping to lessen its reliance on its MS franchise by developing aducanumab for Alzheimer’s, but the high-risk programme failed in March this year, sending the price

Latest news

More from news
Approximately 5 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales in the future; however, it must be noted that it is being developed for the treatment of

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Biogen has begun enrolment in two phase III trials of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics